Skip to main content
letter
. 2016 Feb 10;24(5):1935–1937. doi: 10.1007/s00520-016-3116-3

Table 1.

Posterior odds ratios for febrile neutropenia from all cycles with and without the assumption of consistency for lipegfilgrastim vs. pegfilgrastim

Treatment contrast Direct OR (95 % CI) Indirect OR (95 % CI) p value Combined (MTC) OR (95 % CI)
Lipegfilgrastim vs. pegfilgrastim 1.00 (0.26–3.79) 2.00 (0.47–8.11) 0.76 1.39 (0.54–3.50)